tumor

Every cell has a story: Tumor and immune cell interactions within craniopharyngiomas - EurekAlert

Every cell has a story: Tumor and immune cell interactions within craniopharyngiomas

New MUSC Hollings Cancer Center research shows how Golgi stress affects T-cells' tumor-fighting ability - EurekAlert

How Golgi stress affects T-cells' tumor-fighting ability

Next-gen cell-penetrating antibodies for tumor targeting and RAD51 inhibition - EurekAlert

Polymeric cloak stabilizes cytokine complex to generate tumor-targeted nanosuperagonist - EurekAlert

Strategy to combat breast cancer involves two-pronged attack on enzyme that ‘feeds’ tumor - EurekAlert

Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

Tumor-infiltrating lymphocyte therapy marks a milestone in cancer treatment

Already 30 minutes of exercise increases the proportion of tumor-killing white blood cells in blood

How tumor stiffness alters immune cell behavior to escape destruction - EurekAlert

Spaceflight affects tumor-bearing fruit fly hosts and their parasites

AI predicts tumor-killing cells with high accuracy - EurekAlert

AI predicts tumor-killing cells with high accuracy

Turning a tumor's 'shield' into a weapon against itself

AI tool predicts responses to cancer therapy using information from each cell of the tumor

AI tool predicts responses to cancer therapy using information from each cell of the tumor - EurekAlert

Tumor-killing viruses score rare success in late-stage trial

Scientists Find a Tumor Made of Teeth in The Pelvis of an Ancient Egyptian

FDA approves the first treatment for nasopharyngeal carcinoma, a rare cancer that originates in the nasopharynx. The drug (toripalimab-tpzi) is a next-generation, programmed death receptor-1 monoclonal antibody. Because of the tumor's location (behind the nose), surgery is not usually an option.